Acquired palbociclib resistance in KRAS-mutant lung cancer.
作者信息
Sherr Charles J
机构信息
Charles J. Sherr: Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, TN, USA.
出版信息
Oncotarget. 2018 Aug 28;9(67):32734-32735. doi: 10.18632/oncotarget.26027.
Abstract
摘要
相似文献
1
Acquired palbociclib resistance in KRAS-mutant lung cancer.KRAS 突变型肺癌中获得性帕博西尼耐药性
Oncotarget. 2018 Aug 28;9(67):32734-32735. doi: 10.18632/oncotarget.26027.
2
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer.在KRAS突变型非小细胞肺癌中，帕博西尼耐药导致对成纤维细胞生长因子受体-丝裂原活化蛋白激酶-雷帕霉素靶蛋白驱动的信号通路产生依赖性。
Oncotarget. 2018 Aug 3;9(60):31572-31589. doi: 10.18632/oncotarget.25803.
3
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.MEK与CDK4/6抑制剂联合在KRAS突变型结直肠癌模型中的体内外疗效。
Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.
4
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.曲美替尼与哌柏西利联合放射增敏 KRAS 突变型非小细胞肺癌的体外和体内研究。
Clin Cancer Res. 2016 Jan 1;22(1):122-33. doi: 10.1158/1078-0432.CCR-15-0589.
5
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.上皮-间质转化定义了KRAS突变型肺癌中MEK抑制诱导的受体酪氨酸激酶信号的反馈激活。
Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6.
6
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.上皮-间质转化（EMT）在KRAS突变型肺癌对MEK抑制剂适应性耐药中的关键作用
Small GTPases. 2017 Jul 3;8(3):172-176. doi: 10.1080/21541248.2016.1210369. Epub 2016 Jul 8.
7
Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.帕博西尼，一种选择性 CDK4/6 抑制剂，增强了雷莫芦单抗在 RAS 驱动的非小细胞肺癌中的疗效。
Cancer Lett. 2017 Nov 1;408:130-137. doi: 10.1016/j.canlet.2017.08.031. Epub 2017 Sep 1.
8
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.抑制 CDK4 通过增加细胞凋亡使多药耐药卵巢癌细胞对紫杉醇敏感。
Cell Oncol (Dordr). 2017 Jun;40(3):209-218. doi: 10.1007/s13402-017-0316-x. Epub 2017 Feb 27.
9
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.KRAS 突变型结直肠癌对同时靶向 MEK 和 CDK4/6 的联合疗法的敏感性。
Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14.
10
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.KRAS 突变型结直肠癌细胞模型中对 PI3K 和 mTOR 双重阻断的耐药性导致对受体酪氨酸激酶 EGFR 抑制的联合敏感性。
Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.
引用本文的文献
1
CDK4/6 inhibitors in lung cancer: current practice and future directions.CDK4/6 抑制剂在肺癌中的应用：现状与未来方向。
Eur Respir Rev. 2024 Feb 14;33(171). doi: 10.1183/16000617.0145-2023. Print 2024 Jan 31.
2
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib.阿贝西利、哌柏西利和瑞博西利在代谢转运及耐药机制方面的差异。
Front Pharmacol. 2023 Jul 5;14:1212986. doi: 10.3389/fphar.2023.1212986. eCollection 2023.
3
PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance.PD-0332991 联合顺铂抑制非小细胞肺癌并逆转顺铂耐药性。
Thorac Cancer. 2021 Mar;12(6):924-931. doi: 10.1111/1759-7714.13866. Epub 2021 Feb 3.
本文引用的文献
1
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.CDK4/6 抑制剂：作用机制可能不像以前认为的那么简单。
Cancer Cell. 2018 Jul 9;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023. Epub 2018 May 3.
2
Palbociclib and Letrozole in Advanced Breast Cancer.帕博西尼联合来曲唑治疗晚期乳腺癌。
N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.
3
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.获得性CDK6扩增促进乳腺癌对CDK4/6抑制剂的耐药性以及雌激素受体信号传导和依赖性的丧失。
Oncogene. 2017 Apr 20;36(16):2255-2264. doi: 10.1038/onc.2016.379. Epub 2016 Oct 17.
4
A combinatorial strategy for treating KRAS-mutant lung cancer.一种治疗KRAS突变型肺癌的联合策略。
Nature. 2016 Jun 30;534(7609):647-51. doi: 10.1038/nature18600. Epub 2016 Jun 22.
5
Targeting CDK4 and CDK6: From Discovery to Therapy.靶向细胞周期蛋白依赖性激酶4和6：从发现到治疗
Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11.
6
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.细胞周期蛋白E1和RTK/RAS信号通路通过激活E2F和ETS驱动细胞周期蛋白依赖性激酶抑制剂耐药。
Oncotarget. 2015 Jan 20;6(2):696-714. doi: 10.18632/oncotarget.2673.
7
Targeting RAS-ERK signalling in cancer: promises and challenges.靶向癌症中的 RAS-ERK 信号通路：前景与挑战。
Nat Rev Drug Discov. 2014 Dec;13(12):928-42. doi: 10.1038/nrd4281.
8
Senescence and apoptosis: dueling or complementary cell fates?衰老与凋亡：相互对抗还是相互补充的细胞命运？
EMBO Rep. 2014 Nov;15(11):1139-53. doi: 10.15252/embr.201439245. Epub 2014 Oct 13.
9
CDK inhibitors: positive and negative regulators of G1-phase progression.细胞周期蛋白依赖性激酶抑制剂：G1期进程的正负调节因子
Genes Dev. 1999 Jun 15;13(12):1501-12. doi: 10.1101/gad.13.12.1501.
Zotero 插件